

Application No.: 10/615,809


Attorney Docket No. A-817 (US)

**PENDING CLAIMS**


This listing of claims replaces all previous listings and reflects the amendments that were entered after the Final Action:

1. (Previously Presented) A compound of Formula I

RECEIVED  
CENTRAL FAX CENTER  
JUN 20 2007



wherein R is



wherein R<sup>1</sup> is selected from 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 2,3-dihydro-1H-indolyl, and 1,4-benzodioxanyl; wherein R<sup>1</sup> is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4-methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy;

wherein R<sup>2</sup> is one or more substituents independently selected from

H,  
halo,  
hydroxy,  
amino,  
C<sub>1-6</sub>-alkyl,  
C<sub>1-6</sub>-haloalkyl,  
C<sub>1-6</sub>-alkoxy,  
C<sub>1-2</sub>-alkylamino,  
aminosulfonyl,  
C<sub>3-6</sub>-cycloalkyl,  
cyano,  
C<sub>1-2</sub>-hydroxyalkyl,  
nitro,  
C<sub>2-3</sub>-alkenyl,  
C<sub>2-3</sub>-alkynyl,  
C<sub>1-6</sub>-haloalkoxy,  
C<sub>1-6</sub>-carboxyalkyl,  
4-6-membered heterocyclyl-C<sub>1-6</sub>-alkylamino,  
unsubstituted or substituted phenyl and


Application No.: 10/615,809

Attorney Docket No. A-817 (US)


unsubstituted or substituted 4-6 membered heterocyclyl;

wherein  $R^3$  is substituted or unsubstituted 5-6 membered heterocyclyl; wherein substituted  $R^3$  is substituted with one or more substituents independently selected from halo,  $-OR^4$ ,  $-SR^4$ ,  $-SO_2R^4$ ,  $-CO_2R^4$ ,  $-CONR^4R^4$ ,  $-COR^4$ ,  $-NR^4R^4$ ,  $-SO_2NR^4R^4$ ,  $-NR^4C(O)OR^4$ ,  $-NR^4C(O)R^4$ , cycloalkyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, lower alkyl substituted with  $R^2$ , cyano, nitro, lower alkenyl and lower alkynyl; wherein  $R^4$  is independently selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted  $C_3-C_6$  cycloalkyl, phenyl- $C_{1-6}$ -alkyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-6}$ -alkyl, and lower haloalkyl; wherein  $R^5$  is selected from H,  $C_{1-3}$ -alkyl, optionally substituted phenyl, optionally substituted phenyl- $C_{1-3}$ -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-3}$ -alkyl,  $C_{1-3}$ -alkoxy- $C_{1-2}$ -alkyl and  $C_{1-3}$ -alkoxy- $C_{1-3}$ -alkoxy- $C_{1-3}$ -alkyl; wherein  $R^a$  is selected from H and  $C_{1-2}$ -alkyl; and wherein  $R^b$  and  $R^c$  are independently selected from H and  $C_{1-2}$ -haloalkyl; and pharmaceutically acceptable salts thereof.

2. (Previously Presented) A compound of Formula I'



wherein R is



wherein  $R^1$  is selected from 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 2,3-dihydro-1H-indolyl, and 1,4-benzodioxanyl; wherein  $R^1$  is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano,

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4-methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy;

wherein R<sup>2</sup> is one or more substituents independently selected from

H,  
halo,  
hydroxy,  
amino,  
C<sub>1-6</sub>-alkyl,  
C<sub>1-6</sub>-haloalkyl,

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

C<sub>1-6</sub>-alkoxy,  
C<sub>1-2</sub>-alkylamino,  
aminosulfonyl,  
C<sub>3-6</sub>-cycloalkyl,  
cyano,  
C<sub>1-2</sub>-hydroxyalkyl,  
nitro,  
C<sub>2-3</sub>-alkenyl,  
C<sub>2-3</sub>-alkynyl,  
C<sub>1-6</sub>-haloalkoxy,  
C<sub>1-6</sub>-carboxyalkyl,  
4-6-membered heterocyclyl-C<sub>1-6</sub>-alkylamino,  
unsubstituted or substituted phenyl and  
unsubstituted or substituted 4-6 membered heterocyclyl;

wherein R<sup>3</sup> is substituted or unsubstituted 5-6 membered heterocyclyl; wherein substituted R<sup>3</sup> is substituted with one or more substituents independently selected from halo, -OR<sup>4</sup>, -SR<sup>4</sup>, -SO<sub>2</sub>R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -CONR<sup>4</sup>R<sup>4</sup>, -COR<sup>4</sup>, -NR<sup>4</sup>R<sup>4</sup>, -SO<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>, -NR<sup>4</sup>C(O)OR<sup>4</sup>, -NR<sup>4</sup>C(O)R<sup>4</sup>, cycloalkyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, lower alkyl substituted with R<sup>6</sup>, cyano, nitro, lower alkenyl and lower alkynyl;

wherein R<sup>4</sup> is independently selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, phenyl-C<sub>1-6</sub>-alkyl, optionally substituted 4-6 membered heterocyclyl-C<sub>1-6</sub>-alkyl, and lower haloalkyl;

wherein R<sup>5</sup> is selected from H, C<sub>1-3</sub>-alkyl, optionally substituted phenyl, optionally substituted phenyl-C<sub>1-3</sub>-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1-3</sub>-alkoxy-C<sub>1-2</sub>-alkyl and C<sub>1-3</sub>-alkoxy-C<sub>1-3</sub>-alkoxy-C<sub>1-3</sub>-alkyl;

wherein R<sup>6</sup> is selected from H, halo, hydroxy, amino, C<sub>1-6</sub>-alkoxy, C<sub>1-2</sub>-alkylamino, aminosulfonyl, C<sub>3-6</sub>-cycloalkyl, cyano, nitro, C<sub>1-6</sub>-haloalkoxy, carboxy, 4-6-membered heterocyclyl-C<sub>1-6</sub>-alkylamino, unsubstituted or substituted phenyl and unsubstituted or substituted 4-6 membered heterocyclyl;

wherein R<sup>a</sup> is selected from H and C<sub>1-2</sub>-alkyl; and

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

wherein R<sup>b</sup> and R<sup>c</sup> are independently selected from H and C<sub>1-2</sub>-haloalkyl;  
and pharmaceutically acceptable salts thereof.

3. (Canceled)

4. (Canceled)

5. (Previously Presented) Compound of Claim 2 wherein R<sup>1</sup> is selected from 4,4-dimethyl-1,2,3,4-tetrahydro-isoquinol-7-yl, 2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinol-7-yl, 2,3-dihydro-1H-indolyl, 3,3-dimethyl-2,3-dihydro-1H-indol-6-yl, 1-ethyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl, and 1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl; and pharmaceutically acceptable salts thereof.

6. (Previously Presented) Compound of Claim 5 wherein R<sup>1</sup> is 3,3-dimethyl-2,3-dihydro-1H-indol-6-yl; and pharmaceutically acceptable salts thereof.

7. (Previously Presented) Compound of Claim 5 wherein R<sup>1</sup> is 4,4-dimethyl-1,2,3,4-tetrahydro-isoquinol-7-yl; and pharmaceutically acceptable salts thereof.

8. (Canceled)

9. (Canceled).

10. (Previously Presented) Compound of Claim 2 wherein R<sup>2</sup> is selected from H, chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl;  
and pharmaceutically acceptable salts thereof.

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

11. (Previously Presented) Compound of Claim 10 wherein  $R^2$  is H; and pharmaceutically acceptable salts thereof.

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Previously Presented) Compound of Claim 2 wherein R is selected from (4-pyridyl)-CH<sub>2</sub>-, (4-pyrimidinyl)-CH<sub>2</sub>-, (5-pyrimidinyl)-CH<sub>2</sub>-, (6-pyrimidinyl)-CH<sub>2</sub>-, (4-pyridazinyl)-CH<sub>2</sub>- and (6-pyridazinyl)-CH<sub>2</sub>-; wherein R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino, methylamino, hydroxy, methyl, ethyl, propyl, trifluoromethyl, methoxy and ethoxy; and pharmaceutically acceptable salts thereof.

18. (Canceled)

19. (Previously Presented) Compound of Claim 2 wherein R is selected from (4-pyridyl)-CH<sub>2</sub>-, (2-methylamino-4-pyrimidinyl)-CH<sub>2</sub>-, (4-pyridazinyl)-CH<sub>2</sub>-, (2-methoxy-4-pyridyl)-CH<sub>2</sub>-, (4-pyridazinyl)-CH<sub>2</sub>-, and (2-amino-4-pyrimidinyl)-CH<sub>2</sub>-; and pharmaceutically acceptable salts thereof.

20. (Previously Presented) Compound of Claim 2 wherein  $R^3$  is selected from unsubstituted or substituted 6-membered nitrogen-containing heteroaryl; and wherein substituted  $R^3$  is substituted with one or more substituents independently selected from halo, amino, C<sub>1-3</sub>-alkoxy, hydroxyl, C<sub>1-3</sub>-alkyl and C<sub>1-2</sub>-haloalkyl; and pharmaceutically acceptable salts thereof.

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

21. (Canceled).

22. (Canceled).

23. (Previously Presented) Compound of Claim 2 wherein R<sup>5</sup> is selected from H, piperidinylethyl and methoxyethoxyethyl; wherein R<sup>a</sup> is H; and wherein R<sup>b</sup> and R<sup>c</sup> are independently selected from H and trifluoromethyl; and pharmaceutically acceptable salts thereof.

24. (Previously Presented) Compound of Claim 2 wherein R is (4-pyridyl)-CH<sub>2</sub>-; and pharmaceutically acceptable salts thereof.

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled).

29. (Previously Presented) Compound of Claim 2 wherein R<sup>2</sup> is H or fluoro; and pharmaceutically acceptable salts thereof.

30. (Previously Presented) A Compound of Claim 2 and pharmaceutically acceptable salts thereof selected from

N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-benzamide;

N-(1-acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-benzamide;

N-(4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-[(2-methylamino-pyrimidin-4-ylmethyl)-amino]-benzamide;



Application No.: 10/615,809

Attorney Docket No. A-817 (US)

(*R*)-*N*-(4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-[1-(2-methylamino-pyrimidin-4-yl)-ethylamino]-benzamide;  
*N*-(1-Ethyl-3,3-dimethyl-2,3-dihydro-1*H*-indol-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-benzamide;  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-[(2-methoxy-pyridin-4-ylmethyl)-amino]-benzamide;  
*N*-(3,3-Dimethyl-2,3-dihydro-1*H*-indol-6-yl)-2-[(1-oxy-pyridin-4-ylmethyl)-amino]-benzamide;  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-fluoro-6-[(2-methoxy-pyridin-4-ylmethyl)-amino]-benzamide;  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-fluoro-6-[(2-methoxy-pyridin-4-ylmethyl)-amino]-benzamide;  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-2-[(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)-amino]-benzamide;  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-[(pyridazin-4-ylmethyl)-amino]-benzamide;  
2-[1-(2-Amino-pyrimidin-4-yl)-ethylamino]-*N*-(4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-benzamide;  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-[1-(2-methylamino-pyrimidin-4-yl)-ethylamino]-benzamide; and  
*N*-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-4-fluoro-6-[(2-methoxy-pyridin-4-ylmethyl)-amino]-benzamide.

31. (Original) Compound of Claim 2, and pharmaceutically acceptable salts thereof, comprising *N*-(3,3-dimethyl-2,3-dihydro-1*H*-indol-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-benzamide.

32. (Original) Compound of Claim 2, and pharmaceutically acceptable salts thereof, comprising *N*-(1-acetyl-3,3-dimethyl-2,3-dihydro-1*H*-indol-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-benzamide.

33. (Canceled)

Application No.: 10/615,809

Attorney Docket No. A-817 (US)

34. (Original) Compound of Claim 2, and pharmaceutically acceptable salts thereof, comprising N-(4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-[(2-methylamino-pyrimidin-4-ylmethyl)-amino]-benzamide.

35. (Canceled).

36. (Original) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of Claim 1.

37. (Canceled).

38. (Canceled).

39. (Canceled).

40. (Canceled).

41. (Canceled).

42. (Canceled).

43. (Canceled).

44. (Canceled).

45. (Canceled).